BYORNA
My visitor profile
BYORNA
Description of your activity
-
bYoRNA, a French startup based in Bordeaux, focuses on the bioproduction of therapeutic mRNA for cancer immunotherapies and gene editing. Advantages of in vivo production Vs the incumbent IVT technology:
- more efficient (more neo-antigens) ;
- less side-effects (less immunogenic) ;
- far cheaper.
We have partnered with TRON, the German mRNA research institute created by the founders of BIONTECH. We will test our mRNA in two animal models in 2025 and plan to be GMP within 3 years.
More information
-
bYoRNA is a French early-stage (3M€ of pre-seed funding) startup focusing on the bioproduction of therapeutic mRNA in recombinant yeast cells for cancer immunotherapies and gene editing. The technology is protected by a CNRS patent of which we have the exclusive license.
Advantages of in vivo production Vs the incumbent IVT technology:
- more efficient (more neo-antigens: easier to produce long mRNA >5k nt) ;
- less side-effects (less immunogenic : no dsRNA) ;
- far cheaper.
We have secured partnerships with DYADIC , a Nasdaq company, , and TRON, the German mRNA research institute created by the founders of BIONTECH.
The company has been founded by Thierry ZIEGLER (CTO), a former bioproduction executive from MERCK, SANOFI and CELLECTIS, and Pascal VIGUIE (CEO), a high tech entrepreneur with a past 30M€ exit.
Members of our Scientific Committee include :
- Dr. Uwe Gottschalk (former CSO of Lonza) ;
- Dr. Chantal Pichon (patent inventor, INSERM France + Charity Berlin) ;
- Dr. Jeff Coller (mRNA professor at John Hopkins).
We have already produced 2,000-nucleotide and 8,000-nucleotide mRNAs and we plan to test our mRNA in two animal models by the end of the year. We are cca 3-year away from being GMP.
Emerging company
Pascal VIGUIE
Co-founder & CEO
Date of your company creation:
- Between 1 & 3 years
Main sector
- Biotechnology - Therapeutics and Diagnostics
Address
- Country : FRANCE
- City : Pessac
- Zip Code : 33600
Participation objectives
Partnering objectives
- Out-licensing / collaboration opportunities, Financing / investment opportunities, Network development
Description of my participation objective
- To partner with companies or institutions working on mRNA therapies / therapeutic vaccines.